Showing 2851-2860 of 4063 results for "".
- Ophthotech Announces Results from Phase 2a Safety Trial of Zimura in Combination with Lucentis in Wet AMDhttps://modernod.com/news/ophthotech-announces-results-from-phase-2a-safety-trial-of-zimura-in-combination-with-lucentis-in-wet-amd/2479673/Ophthotech announced the results from its phase 2a safety trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). This trial was designed to evaluate the safety of different dosage regimens of Zimura combinat
- Johnson & Johnson Vision to Showcase New Data and Interactive Experiences at 2018 AAOpthttps://modernod.com/news/johnson-johnson-vision-to-showcase-new-data-and-interactive-experiences-at-2018-aaopt/2479707/Johnson & Johnson Vision will highlight new data at the 2018 American Academy of Optometry Annual Meeting (Academy 2018), held November 7-10 in San Antonio, Texas. Two paper presentations highlighting visual performance of photochromic contact lenses were designated among the “Most Newsworthy
- EyePoint Pharmaceuticals Presents Positive Yutiq 24-month Follow-up Data at AAOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutuq-24-month-follow-up-data-at-aao/2479724/EyePoint Pharmaceuticals announced the presentation of 24-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Th
- Oyster Point Announces Positive Results From Two Phase 2b Clinical Trials of Investigational Treatments for Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-positive-results-from-two-phase-2b-clinical-trials-of-investigational-treatments-for-dry-eye-disease/2479733/Oyster Point Pharma announced results from the ONSET and RAINIER studies, two separate phase 2b clinical trials evaluating the company’s novel therapies for the treatment of dry eye disease (DED). Both studies, presented at the Ophthalmology Innovation Summit (OIS) meeting in Chicago, demonstrate
- EyeMD EMR Healthcare Systems to Debut its EyeMD Electronic Medical Records 2.0 Releasehttps://modernod.com/news/eyemd-to-debut-its-eyemd-electronic-medical-records-2-0-release/2479739/EyeMD EMR Healthcare Systems, a provider of electronic medical records software designed specifically for ophthalmologists, announced the debut of EyeMD EMR 2.0 at the 2018 American Academy of Ophthalmology’s Annual Meeting in Chicago. “EyeMD EMR 2.0 is the result of years of research and
- Alcon to Showcase Latest Innovations at American Academy of Ophthalmology 2018 Annual Meetinghttps://modernod.com/news/alcon-to-showcase-latest-innovations-at-american-academy-of-ophthalmology-2018-annual-meeting/2479748/Alcon will showcase several advancements in ophthalmology through a robust booth presence, a series of live demonstrations, and interactive symposia during the American Academy of Ophthalmology (AAO) 2018 annual meeting, taking place October 27-30 in Chicago, IL. “We are very excited to e
- Non-Contact Panretinal Photocoagulation for Navilas 577s Introduced at AAO 2018https://modernod.com/news/non-contact-panretinal-photocoagulation-for-navilas-577s-introduced-at-aao-2018/2479753/At the AAO 2018 meeting in Chicago, OD-OS is launching a new widefield objective which brings non-contact panretinal photocoagulation with access to the far periphery (ora serrata) to the Navilas 577s Laser System. The new option for peripheral treatments can further enhance compliance of sensiti
- OWL to Host Signature Event and Awards Ceremony at AAO 2018https://modernod.com/news/owl-to-host-signature-event-and-awards-ceremony-at-aao-2018/2479767/OWL: Advancing Diversity in Leadership (OWL) announced that it will host its annual OWL Signature Event and Awards Ceremony at the American Academy of Ophthalmology (AAO). OWL’s largest event of the year will take place on Sunday, October 28, 2018 from 5:30-7:00 p.m., at Revel Motor Row in Chicag
- Santen Announces Initiation of Phase 3 Clinical Program (SPECTRUM) Evaluating Glaucoma Treatment Omidenepag Isopropyl (DE-117)https://modernod.com/news/santen-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension/2479772/Santen announced the initiation of the pivotal phase 3 development program (SPECTRUM) in the United States, evaluating the investigational use of omidenepag isopropyl (DE-117), a selective agonist for the prostanoid receptor EP2, for the treatment of glaucoma or o
- Nicox Provides Third Quarter 2018 Business Update and Financial Highlightshttps://modernod.com/news/nicox-provides-third-quarter-2018-business-update-and-financial-highlights/2479778/Nicox SA provided upcoming milestones and operational highlights, as well as revenue and cash position for Nicox and its subsidiaries, as of September 30, 2018. Key Upcoming Milestones Q1 2019: Planned invest